IGF1 and melanoma: We demonstrated that IGF-1 limits the effects of MEK1/2 inhibition in melanoma cells (Figure 5A), while siRNA, by preventing IGF-1R de novo synthesis with a proportional, balanced overall decrease of its signaling, greatly increases the efficacy of MAPK targeting (Figure 5B).